BioTissue Stock

biotissue.comHealthcare / BioTech & PharmaFounded: 2006

TissueTech manufactures ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries.

Register To Buy and Sell Shares

For more details on financing and valuation for BioTissue, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access BioTissue’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like BioTissue.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About BioTissue’s Stock

Can you buy BioTissue’s stock?
BioTissue is not publicly traded on NYSE or NASDAQ in the U.S. To buy BioTissue’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell BioTissue’s stock?
Yes, you can sell stock of a private company like BioTissue. Forge can help you sell your BioTissue stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is BioTissue’s stock price?
BioTissue is a privately held company and therefore does not have a public stock price. However, you may access BioTissue’s private market stock price with Forge Data.
What is BioTissue’s stock ticker symbol?
BioTissue does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Aspect Biosystems and Novo Nordisk to Tackle Type 1 Diabetes and Obesity
Aspect Biosystems and Novo Nordisk are collaborating on a $2.6 billion project to develop therapeutics for type 1 diabetes and obesity. The companies aim to create 3D, biologically functional tissues containing insulin-producing cells that can be implanted without the need for immunosuppressive drugs. The partnership will fund up to four products for the treatment of diabetes and/or obesity, with Aspect eligible to receive up to $650 million per project based on future milestones, plus royalties on product sales.
Newcastle scientists 3D Bio-Tissues produce and taste world’s first 100% cultivated meat steak
Newcastle-based 3D Bio-Tissues (3DBT) has produced the world's first 100% cultivated pork steak, which replicates the flavour and texture of traditional pork. The meat was made using 3DBT's patented, serum-free and animal-free cell booster, City-mixTM. 3DBT, owned by BSF Enterprise plc, plans to produce a full-scale fillet of cultivated pork and work with manufacturers and supermarkets to distribute the product.
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.